Sr-12813 (2-(3,5-二叔丁基-4-羟基苯基)乙烯-1,1-二基)双(膦酸)四乙酯
CAS 126411-39-0 MFCD00888473
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Cholesterol and Cholesterol Metabolism, D to K, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, GlaxoSmithKline, Hydroxymethylglutaryl-CoA Reductase, Lipids in Cell Signaling, S, 生化试剂, 生物活性小分子, 甲羟戊酸途径中的抑制剂和激活剂, 癌症中的甲羟戊酸途径, 癌症代谢, 癌症研究, 细胞信号转导和神经科学, 细胞生物学, 酶、抑制剂和底物
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, Cancer Metabolism, Cancer Research,
相关文献及参考
- [2]. Jiang W, et al. Forward genetic screening for regulators involved in cholesterol synthesis using validation-based insertional mutagenesis. PLoS One. 2014 Nov 26;9(11):e112632.
- [3]. Sergio C Chai, et al. Small-molecule modulators of PXR and CAR. Biochim Biophys Acta.2016 Sep;1859(9):1141-1154.
- [1]. Berkhout T, et al. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1996 Jun 14;271(24):14376-82.
- [1]. Berkhout T, et al. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1996 Jun 14;271(24):14376-82.
- [2]. Jiang W, et al. Forward genetic screening for regulators involved in cholesterol synthesis using validation-based insertional mutagenesis. PLoS One. 2014 Nov 26;9(11):e112632.
- [3]. Sergio C Chai, e